H.E.L.P. LDL-apheresis clinical experience in ItalyStefanutti Claudia, Shafii Mahnaz, Di Giacomo Serafina, Morozzi Claudia, Mazzilli Sara and the Italian Multicenter Study on Low-Density-Lipoprotein -Apheresis Working GroupExtracorporeal Therapeutic Techniques Unit - Immunohematology and Transfusion MedicineDepartment of Molecular Medicine - University of Rome ‘La Sapienza’, ‘Umberto I’ Hospital 155, V.le del Policlinico Rome I-00161 EU The clinical benefits of LDL-apheresis (LDL_a) have been demonstrated in numerous studies: the H.E.L.P. LDL-Apheresis Multicenter Study, the LDL-Apheresis Atherosclerosis Regression Study (LAARS), the German Multicenter LDL-Apheresis Trial, and the Familial Hypercholesterolemia (FH) Regression Study. The use, efficacy and safety of the heparin-induced extra-corporeal LDL-precipitation (H.E.L.P.®)- LDL –apheresis (H.E.L.P.-LDL_a) for the long-term management of patients with severe dyslipidemia has been studied in a single center (Rome, “La Sapienza” University) open retrospective survey. The data from 22 patients were evaluated accounting for 1437 H.E.L.P. LDL_a procedures. The Plasmat™ Futura System is the device for H.E.L.P.-LDL_a. used selectively to remove apolipoprotein B100-containing-lipoproteins in patients with severe dyslipidemia in our center. Regular H.E.L.P. LDL_a treatment was administered weekly or biweekly in Homozygous and Heterozygous FH patients. H.E.L.P. LDL_a treatment was beneficial and safe in patients with refractory hypercholesterolemia genetically determined, and coronary artery disease. The increasing use of H.E.L.P. LDL_a in Italy was recently reported also by the coordination (Rome) of the Italian Multicenter Study on LDL-apheresis Working Group (unpublished data). Among 101 patients submitted to LDL_a in 18 Italian centers, 41 have been treated with H.E.L.P. LDL_a.

H.E.L.P. LDL-apheresis clinical experience in Italy / Stefanutti, Claudia; M., Shafii; DI GIACOMO, Serafina; Morozzi, Claudia; S., Mazzilli; The Italian Multicenter Study O. N., Low Density Lipoprotein Apheresis Working Group. - In: THERAPEUTIC APHERESIS AND DIALYSIS. - ISSN 1744-9979. - STAMPA. - 15:4(2011), pp. A24 n.69-A24 n.69. (Intervento presentato al convegno 8th Congress of the ISFA tenutosi a Vienna nel September 2011) [10.1111/j.1744-9987.2011.01006.x].

H.E.L.P. LDL-apheresis clinical experience in Italy

STEFANUTTI, Claudia;DI GIACOMO, SERAFINA;MOROZZI, CLAUDIA;
2011

Abstract

H.E.L.P. LDL-apheresis clinical experience in ItalyStefanutti Claudia, Shafii Mahnaz, Di Giacomo Serafina, Morozzi Claudia, Mazzilli Sara and the Italian Multicenter Study on Low-Density-Lipoprotein -Apheresis Working GroupExtracorporeal Therapeutic Techniques Unit - Immunohematology and Transfusion MedicineDepartment of Molecular Medicine - University of Rome ‘La Sapienza’, ‘Umberto I’ Hospital 155, V.le del Policlinico Rome I-00161 EU The clinical benefits of LDL-apheresis (LDL_a) have been demonstrated in numerous studies: the H.E.L.P. LDL-Apheresis Multicenter Study, the LDL-Apheresis Atherosclerosis Regression Study (LAARS), the German Multicenter LDL-Apheresis Trial, and the Familial Hypercholesterolemia (FH) Regression Study. The use, efficacy and safety of the heparin-induced extra-corporeal LDL-precipitation (H.E.L.P.®)- LDL –apheresis (H.E.L.P.-LDL_a) for the long-term management of patients with severe dyslipidemia has been studied in a single center (Rome, “La Sapienza” University) open retrospective survey. The data from 22 patients were evaluated accounting for 1437 H.E.L.P. LDL_a procedures. The Plasmat™ Futura System is the device for H.E.L.P.-LDL_a. used selectively to remove apolipoprotein B100-containing-lipoproteins in patients with severe dyslipidemia in our center. Regular H.E.L.P. LDL_a treatment was administered weekly or biweekly in Homozygous and Heterozygous FH patients. H.E.L.P. LDL_a treatment was beneficial and safe in patients with refractory hypercholesterolemia genetically determined, and coronary artery disease. The increasing use of H.E.L.P. LDL_a in Italy was recently reported also by the coordination (Rome) of the Italian Multicenter Study on LDL-apheresis Working Group (unpublished data). Among 101 patients submitted to LDL_a in 18 Italian centers, 41 have been treated with H.E.L.P. LDL_a.
2011
8th Congress of the ISFA
04 Pubblicazione in atti di convegno::04d Abstract in atti di convegno
H.E.L.P. LDL-apheresis clinical experience in Italy / Stefanutti, Claudia; M., Shafii; DI GIACOMO, Serafina; Morozzi, Claudia; S., Mazzilli; The Italian Multicenter Study O. N., Low Density Lipoprotein Apheresis Working Group. - In: THERAPEUTIC APHERESIS AND DIALYSIS. - ISSN 1744-9979. - STAMPA. - 15:4(2011), pp. A24 n.69-A24 n.69. (Intervento presentato al convegno 8th Congress of the ISFA tenutosi a Vienna nel September 2011) [10.1111/j.1744-9987.2011.01006.x].
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/384871
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? ND
social impact